PRESS RELEASE published on 01/22/2024 at 08:30, 2 years 9 months ago Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024. Abivax Obefazimod Ulcerative Colitis Crohn’s Disease Clinical Trials
PRESS RELEASE published on 10/24/2023 at 22:05, 3 years ago Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE published on 10/20/2023 at 16:00, 3 years ago Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PRESS RELEASE published on 10/20/2023 at 15:45, 3 years ago Abivax announces trading resumption of its ordinary shares on Euronext Paris
PRESS RELEASE published on 10/20/2023 at 15:00, 3 years ago Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE published on 10/20/2023 at 08:45, 3 years ago Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PRESS RELEASE published on 10/19/2023 at 00:00, 3 years ago Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
PRESS RELEASE published on 10/16/2023 at 17:40, 3 years ago Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
PRESS RELEASE published on 10/02/2023 at 18:00, 3 years ago Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023
PRESS RELEASE published on 09/29/2023 at 23:00, 3 years 1 month ago Abivax files registration statement for proposed initial public offering in the United States
Published on 10/30/2026 at 23:35, 2 days ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 4 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 8 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 13 hours 6 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 18 hours 41 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 7 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 11 hours ago Capital increase through exercise of subscription rights
